Aerie Pharmaceuticals and DSM Biomedical have expanded a collaborative research, development and license agreement, according to a press release.
The original agreement, announced in July 2017, was for the evaluation of sustained delivery of Aerie compounds using DSM’s bioerodible polyesteramide polymer technology, focusing on retinal diseases, the release said. Implants containing AR-13503 have had promising preclinical results.
The new agreement will allow Aerie to have a worldwide exclusive license for all ophthalmic indications of DSM’s polyesteramide polymer technology and gain
Uncategorized